Advanced Prostate Cancer
5,185 members4,850 posts

Interesting result for BRCA patients from ASCO2018

"Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant

prostate cancer receiving first-line abiraterone and enzalutamide."

"Conclusions: Outcomes to first

line NHT appeared better in mCRPC patients harboring germline BRCA/ATM mutations (vs. no

mutations), but not for patients with other non-BRCA/ATM germline mutations. These results support the hypothesis that AR may promote DNA repair, and that inhibiting AR in the context of homologous recombination deficiency may lead to synthetic lethality."

You may also like...